2009～2015年浙江省11家医院肺癌患者表皮生长因子受体酪氨酸激酶抑制药使用调查

Utilization Investigation of EGFR-TKI in the Patients with Lung Cancer in 11 Hospitals of Zhejiang Province during 2009 and 2015

目的:了解2009~2015年浙江省11家医院肺癌患者表皮生长因子受体酪氨酸激酶抑制药(EGFR-TKI)的利用现状,分析其用药合理性。方法:抽取2009~2015年浙江省11家医院每年40天的医嘱数据,对肺癌患者使用EGFR-TKI的用药金额、用药频度(DDDs)、限定日费用(DDC)以及药物利用指数(DUI)进行统计分析。结果:埃克替尼、厄洛替尼和吉非替尼是目前最主要的3种EGFR-TKI,其中埃克替尼2013年之后才开始使用。EGFR-TKI的用药总金额总体呈上升趋势,2015年的销售总金额是2009年的4.67倍;厄洛替尼的DDDs总体呈降低趋势,吉非替尼和埃克替尼的DDDs逐年升高;DDC排序最高的是厄洛替尼,吉非替尼次之,埃克替尼最低;3种靶向药物的DUI值均在1左右。结论:浙江省11家医院EGFR-TKI的用量逐年升高,但使用相对合理。

Objective： To investigate the utilization status of epidermal growth factor receptor tyrosine kinase inhibitor （ EGFR- TKI） in 11 hospitals of Zhejiang province from 2009 to 2015, and to analyze the use rationality. Methods： The doctor＇ s advice in 40 days annually was collected in 11 hospitals of Zhejiang province from 2009 to 2015, and the drug consumption, frequency of utilization （ DDDs）, defined daily cost （DDC） and drug utilization index （DUI） were analyzed for the patients with lung cancer treated with EG- FR-TKI. Results： Icotinib, erlotinib and gefitinib were the three prevalent EGFR-TKIs used in Zhejiang province, and icotinib started to be used in clinics in 2013. The overall cost of EGFR-TKIs increased year by year during 2009 and 2015, and the total amount of sales increased by 4.67 times in 2015 when compared with that in 2009. Generally, the DDDs value of erlotinib showed a decreasing trend, however, that of icotinib and gefitinib rose year by year during 2009 and 2015. Erlotinib had the highest DDC followed by ge- fitinib and icotinib. The mean value of DUI of the three targeted drugs was about 1. Conclusion： The utilization of EGFR-TKI is rea- sonable in 11 hospitals of Zhejiang province with increasing comsuption.